Predicting the risk of bone metastasis in prostate cancer

Alberto Briganti, Nazareno Suardi, Andrea Gallina, Firas Abdollah, Giacomo Novara, Vincenzo Ficarra, Francesco Montorsi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The ability to identify prostate cancer patients at 'high risk' for bone metastasis development could allow early selection of those most likely to benefit from interventions to prevent or delay bone metastasis. This review is aimed to identify potential predictors of risk for bone metastasis in newly diagnosed patients and in those who have already received treatment.At diagnosis, established predictors of prostate cancer aggressiveness (e.g. PSA level, clinical stage, Gleason score) can identify patients at risk for bone metastasis. Following treatment of the disease, increasing evidence suggests that absolute PSA levels and other measures of PSA kinetics are useful to aid prediction of bone metastasis risk in patients both with and without a history of ADT. However, which PSA parameter most accurately predicts risk and the cut-off values that should be employed are unclear. Inclusion of PSA parameters to identify a high risk population may be beneficial in whom bone-modifying treatments are being considered. Other novel (but unvalidated) biomarkers that potentially predict the development of bone metastases have been identified, although it is unclear whether they will have value as independent markers or when combined with other parameters (e.g. measures of PSA kinetics). Further prospective studies of PSA kinetics and other predictive markers are, therefore, required to define the optimal criteria for identifying patients at high risk of bone metastases and those who are most likely to benefit from intensive monitoring and therapeutic intervention.

Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalCancer Treatment Reviews
Volume40
Issue number1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Bone Development
Neoplasm Grading
Therapeutics
Biomarkers
Prospective Studies
Population

Keywords

  • Bone metastasis
  • Gleason score
  • Prostate cancer
  • PSA kinetics
  • PSA level
  • Risk factor

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Predicting the risk of bone metastasis in prostate cancer. / Briganti, Alberto; Suardi, Nazareno; Gallina, Andrea; Abdollah, Firas; Novara, Giacomo; Ficarra, Vincenzo; Montorsi, Francesco.

In: Cancer Treatment Reviews, Vol. 40, No. 1, 02.2014, p. 3-11.

Research output: Contribution to journalArticle

Briganti, Alberto ; Suardi, Nazareno ; Gallina, Andrea ; Abdollah, Firas ; Novara, Giacomo ; Ficarra, Vincenzo ; Montorsi, Francesco. / Predicting the risk of bone metastasis in prostate cancer. In: Cancer Treatment Reviews. 2014 ; Vol. 40, No. 1. pp. 3-11.
@article{e8b294d5accc48c3b4b3bcf282c99d23,
title = "Predicting the risk of bone metastasis in prostate cancer",
abstract = "The ability to identify prostate cancer patients at 'high risk' for bone metastasis development could allow early selection of those most likely to benefit from interventions to prevent or delay bone metastasis. This review is aimed to identify potential predictors of risk for bone metastasis in newly diagnosed patients and in those who have already received treatment.At diagnosis, established predictors of prostate cancer aggressiveness (e.g. PSA level, clinical stage, Gleason score) can identify patients at risk for bone metastasis. Following treatment of the disease, increasing evidence suggests that absolute PSA levels and other measures of PSA kinetics are useful to aid prediction of bone metastasis risk in patients both with and without a history of ADT. However, which PSA parameter most accurately predicts risk and the cut-off values that should be employed are unclear. Inclusion of PSA parameters to identify a high risk population may be beneficial in whom bone-modifying treatments are being considered. Other novel (but unvalidated) biomarkers that potentially predict the development of bone metastases have been identified, although it is unclear whether they will have value as independent markers or when combined with other parameters (e.g. measures of PSA kinetics). Further prospective studies of PSA kinetics and other predictive markers are, therefore, required to define the optimal criteria for identifying patients at high risk of bone metastases and those who are most likely to benefit from intensive monitoring and therapeutic intervention.",
keywords = "Bone metastasis, Gleason score, Prostate cancer, PSA kinetics, PSA level, Risk factor",
author = "Alberto Briganti and Nazareno Suardi and Andrea Gallina and Firas Abdollah and Giacomo Novara and Vincenzo Ficarra and Francesco Montorsi",
year = "2014",
month = "2",
doi = "10.1016/j.ctrv.2013.07.001",
language = "English",
volume = "40",
pages = "3--11",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Predicting the risk of bone metastasis in prostate cancer

AU - Briganti, Alberto

AU - Suardi, Nazareno

AU - Gallina, Andrea

AU - Abdollah, Firas

AU - Novara, Giacomo

AU - Ficarra, Vincenzo

AU - Montorsi, Francesco

PY - 2014/2

Y1 - 2014/2

N2 - The ability to identify prostate cancer patients at 'high risk' for bone metastasis development could allow early selection of those most likely to benefit from interventions to prevent or delay bone metastasis. This review is aimed to identify potential predictors of risk for bone metastasis in newly diagnosed patients and in those who have already received treatment.At diagnosis, established predictors of prostate cancer aggressiveness (e.g. PSA level, clinical stage, Gleason score) can identify patients at risk for bone metastasis. Following treatment of the disease, increasing evidence suggests that absolute PSA levels and other measures of PSA kinetics are useful to aid prediction of bone metastasis risk in patients both with and without a history of ADT. However, which PSA parameter most accurately predicts risk and the cut-off values that should be employed are unclear. Inclusion of PSA parameters to identify a high risk population may be beneficial in whom bone-modifying treatments are being considered. Other novel (but unvalidated) biomarkers that potentially predict the development of bone metastases have been identified, although it is unclear whether they will have value as independent markers or when combined with other parameters (e.g. measures of PSA kinetics). Further prospective studies of PSA kinetics and other predictive markers are, therefore, required to define the optimal criteria for identifying patients at high risk of bone metastases and those who are most likely to benefit from intensive monitoring and therapeutic intervention.

AB - The ability to identify prostate cancer patients at 'high risk' for bone metastasis development could allow early selection of those most likely to benefit from interventions to prevent or delay bone metastasis. This review is aimed to identify potential predictors of risk for bone metastasis in newly diagnosed patients and in those who have already received treatment.At diagnosis, established predictors of prostate cancer aggressiveness (e.g. PSA level, clinical stage, Gleason score) can identify patients at risk for bone metastasis. Following treatment of the disease, increasing evidence suggests that absolute PSA levels and other measures of PSA kinetics are useful to aid prediction of bone metastasis risk in patients both with and without a history of ADT. However, which PSA parameter most accurately predicts risk and the cut-off values that should be employed are unclear. Inclusion of PSA parameters to identify a high risk population may be beneficial in whom bone-modifying treatments are being considered. Other novel (but unvalidated) biomarkers that potentially predict the development of bone metastases have been identified, although it is unclear whether they will have value as independent markers or when combined with other parameters (e.g. measures of PSA kinetics). Further prospective studies of PSA kinetics and other predictive markers are, therefore, required to define the optimal criteria for identifying patients at high risk of bone metastases and those who are most likely to benefit from intensive monitoring and therapeutic intervention.

KW - Bone metastasis

KW - Gleason score

KW - Prostate cancer

KW - PSA kinetics

KW - PSA level

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=84887043720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887043720&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2013.07.001

DO - 10.1016/j.ctrv.2013.07.001

M3 - Article

C2 - 23896177

AN - SCOPUS:84887043720

VL - 40

SP - 3

EP - 11

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 1

ER -